Drugs / REZORSTOBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05565417 | Nov 2022 → Jan 2026 overdue | Burkitt lymphoma, Hodgkins lymphoma, colorectal cancer, diffuse large B-cell lymphoma +8 | Immunitas Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Immunitas Therapeutics | Results Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting immunitastx.com ↗
IMT-009 was generally well tolerated as monotherapy and in combination with fruquintinib, demonstrating early signs of anti-tumor activity in heavily pretreated patients |
| 2026-04-13 | Immunitas Therapeutics | Results A First in Human, Dose Escalation and Biomarker Cohort Expansion of IMT-009 (anti CD161) in advanced cancer and Phase 1b combination with Fruquintinib in Microsatellite Stable Colorectal Cancer immunitastx.com ↗
Anti-tumor activity was observed as both mono- and combo-therapy |
| 2024-04-08 | Immunitas Therapeutics | Results Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting immunitastx.com ↗
Preclinical data expand potential of IMT-009, confirming presence of CD161 expressing T cells in anti-PD1 non-responder tumors and demonstrating enhanced T cell mediated cytotoxicity with combination treatment of IMT-009 and anti-PD1 |
| 2024-03-20 | Immunitas Therapeutics | Results Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy immunitastx.com ↗
IMT009 treatment reverses CLEC2D/CD161 mediated inhibition and enhanced CD8 T cell mediated cytotoxicity. |
| 2022-11-11 | Immunitas Therapeutics | Results Immunitas Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Cancer Immunotherapy IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting immunitastx.com ↗
Preclinical data confirm that IMT-009 binds with high affinity and selectivity to CD161, a cell surface inhibitory receptor that is broadly expressed on NK and a subset of memory CD4+ and CD8+ T cells. |
| 2022-11-04 | Immunitas Therapeutics | Results 2022 SITC Annual Meeting: Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D immunitastx.com ↗
Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D |
| 2022-09-21 | Immunitas Therapeutics | Regulatory Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies immunitastx.com ↗
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies |
All press releases naming this drug 11 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REZORSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314872 ↗ |
| Known as | IMT-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565417 ↗ |
| Action | Inhibit | “Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity” NCT05565417 ↗ |
| Modality | Monoclonal antibody | “IMT-009 is an Fc-attenuated monoclonal antibody” NCT05565417 ↗ |
| Route | Intravenous | “Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.” NCT05565417 ↗ |